Close Menu

BioChain

Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.

The deal covers a panel of blood-based DNA methylation biomarkers derived in part from Epigenomics' bronchoalveolar lavage-based Epi proLung BL test.

The samples, which include non-small cell lung cancer samples, will be screened for cancer fusions, copy number variations, SNPs, and insertions and deletions.

The Chinese guideline recommends the use of the Septin-9 DNA methylation assay as the standard of care for early colorectal cancer screening.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.